Adrienne Schneider

Adrienne is a retired American Airlines executive with over 20 years of corporate benefits, operations, and human resources experience.  During her career, she has developed deep expertise in identifying organizational needs matched with practical solutions. This experience includes evaluating hundreds of health care and health care technology companies and their ability to meet complex demands in a constantly evolving landscape.  She created an innovative, best-in-class ecosystem of health care and benefits programs for 100,000 employees of the world’s largest airline. She was accountable for oversight of challenging integrations from ideation through to execution.

She is the founder and CEO of The Camille Group, a strategic consulting firm.  Through her experience with working with sophisticated stakeholders in health care and employee benefits, her firm offers evidence-based solutions tailored to client needs.  The firm’s personalized and collaborative approach helps clients identify opportunities for revenue growth, strategies for effective operational execution, and provides ongoing advisory services to help ensure sustained success.

Moran Shochat-Snir leads the Emerging platforms and Data teams at Invitae (NVTA), a leading genetics company whose mission is to bring comprehensive genetic information into mainstream medicine. Moran is the co-founder and former CEO of Clear Genetics, which was acquired by Invitae in November 2019. Clear Genetics developed software to thoughtfully scale delivery of genetic services and integrate it into routine patient care. Prior, Moran was at Medtronic, where she held several key roles, including leading business strategy, portfolio prioritization, and business development. She was also the co-founder of MorNetware, an Israeli software company that scales delivery of prenatal carrier screening. Moran was an officer in Israel Defense Forces’ Elite software unit, then studied Biomedical Engineering at Tel Aviv University for her Bachelors and Masters Degrees. She has an MBA from the Wharton Business School and is a Y combinator Alum.

Josh is a health care product, operations and strategy leader with a 20-year track record of successfully creating, bringing to market, and selling employer-, payer- and provider-facing products at industry-leading healthcare companies. Josh’s areas of expertise include Medicare, telehealth, post-acute care, employer group benefits, complex disease management, product development and management, and finance.

Josh holds a BS in Nutritional Science from Cornell University and an MBA in Finance and Investments from the Zicklin School of Business (Baruch College, City University of New York)

Dr. Avi Tsur, M.D is the Founder and Director of the Sheba Women’s Health Innovation Center, a collaborative effort or ARC, the Sheba Department of Obstetrics & Gynecology and the Gertner Institute for Health Policy and Epidemiology.

Serves as Head of the Sheba Beyond Women’s Health Telemedicine Services providing cutting edge remote healthcare services across Israel and Beyond.

Clinically trained in the Hadassah Medical School, Sheba Medical Center and Stanford University Medical Center, and clinically serves as attending physician at the Sheba Antepartum (high-risk pregnancy) Department, High-risk Pregnancy Clinics and the Obstetrics and Gynecology Ultrasound Unit.

Leading a National Ministry of Health Committee, promoting telemedicine in women’s healthcare.

Dr. Tsur holds patents for several predictive machine learning models in the field of Obstetrics and Gynecology, is the founder of and was the lead medical inventor of the Lioness, a mechanical device for prevention of preterm birth currently commercialized by Pregnantech.

Serves as principal investigator of several cutting edge studies –  PTBiome, precision gestational diabetes, and remote postdate fetal monitoring.  Author of 35 peer reviewed manuscripts and three book chapters.

Mentor at Biodesign Israel and the and at the Interdisciplinary Center Herzliya (IDC) program in Healthcare Innovation.

Tom consults to health systems, independent providers, payors, private equity firms and others on value-based care, pharmacy cost management, and patient engagement. Mr. Davis recently finished an assignment as Senior Vice President at Somatus, a managed kidney care company. He has also served as Market President for JenCare/ChenMed in Atlanta, a capitated medical practice serving low-income Medicare Advantage patients.

For 16 years Tom served as Senior Vice President at Coventry Health Care running health plans, pharmacy programs, product development, digital engagement, and product development. In 2013 the company was sold to Aetna.

Mr. Davis has also held leadership positions with United Healthcare, MetraHealth, and Prudential Health Care System. Earlier in his career he worked in management consulting and private equity investing at APM and E.M. Warburg Pincus. Mr. Davis holds an MBA from the Wharton School and a BA in Religion from Wesleyan University. He lives in Atlanta, Georgia.

Yael leads the Nutrino Health business as part of Medtronic Diabetes. As CEO of Nutrino, she led the company to early revenue and successful acquisition in 2018. Previously, Yael held multiple commercial roles: VP of Business Development at Sensible Medical, VP Marketing at American Well, and Director care management marketing at TriZetto (acquired by Cognizant). Yael holds a BA in psychology from Hebrew University and an MBA from MIT Sloan School of Management.

Venture Capitalist and Investment Banker, Ran Reske has turned his decades of experience steering hyper-growth businesses into building his own enterprise with Resident, a house of digitally-native brands that includes Nectar, DreamCloud, Level, Awara, Wovenly and Bundle. Under Ran’s dynamic leadership, the company boasted nearly $250 million in gross sales in 2018, its second year in business.

Alongside co-CEO Eric Hutchinson, Ran oversees all aspects of the business with a deliberate concentration on operational efficiency, strategic partnerships, manufacturing, and customer service to accelerate the company’s overall growth trajectory. As Resident continues to expand its portfolio of brands across the home goods category, he is laser-focused on talent acquisition and building a highly productive, diversified workforce that now includes 250 employees, and counting, across 5 countries and 15 cities.

Prior to launching Resident, Ran led early to late-stage venture investments with Norwest Venture Partners, where he focused on companies in e-commerce, media and mobile. He has also spearheaded corporate development divisions of both Amdocs and Pamplona Capital Management, and held roles in the investment banking division of Citigroup. In that role, Ran focused efforts on strategic advisory assignments for transactions like M-Systems’ $1.3 billion acquisition and Cellcom’s $400 million IPO.

Born in Israel and raised in Kenya, Ran takes pride in being a global citizen who currently resides in San Francisco with his wife and two sons.

A medical device industry veteran with more than 25 years experience, Chip is currently founder and CEO of Regatta Medical, focusing on acquiring companies and assets in the products and services areas of the medical device industry.

Chip previously served as CEO of Creganna Medical, a leading Ireland-based supplier to the minimally invasive medical device industry. After a successful three year effort to focus the company on higher growth markets and improve operational performance, Creganna Medical was sold to TE Connectivity in 2016. Preceding Creganna, Chip was an Entrepreneur-in-Residence within the FDA at CDRH in 2012-13. He co-led the Innovation Pathway team focused on streamlining aspects of medical device clinical trials in the U.S.  Prior to his work at FDA, Chip had a long and distinguished career at Abbott, including President of Abbott Vascular, Abbott’s cardiovascular device division, where he led the organization from a small vessel closure business through acquisitions and organic growth to global leadership in the drug-eluting stent market with the launch of Xience in the U.S., Japan, and China. Abbott Vascular became a multi-billion dollar division of Abbott.

Chip earned a bachelor’s degree in Chemical Engineering from the Massachusetts Institute of Technology and a master’s degree in Business Administration from Harvard Business School.

With a distinguished career in health care spanning more than thirty years, Jim is a Founder and Managing Partner of Tyree & D’Angelo Partners (TDP), a private equity firm focused on investments in promising, underperforming businesses in the lower-middle market.

Prior to founding TDP in 2012, Jim had an outstanding 15 year career at Abbott, holding executive positions in its pharmaceutical and nutrition businesses. Jim was involved in many of the company’s major acquisitions and was responsible for the restructuring of TAP, Abbott’s joint venture with Takeda Chemicals of Japan. Jim served as Executive Vice President, Pharmaceutical Products, Abbott’s largest business, and was also directly responsible for establishing and managing Abbott Global Nutrition, Abbott’s second largest operating division. Jim also served as President of Abbott Biotech Ventures. Prior to his career at Abbott, Jim was President of Sugen, Inc., a biotech company focused on oncology, and held management positions at Bristol-Myers Squibb and Pfizer.

Jim currently serves or has served as an independent director of a number of privately and publicly held companies. He is also a member of The Council of Advisors at the University of Chicago Graduate School of Business (Booth). He earned his MBA from the Kelley School of Business at Indiana University, as well as two bachelor degrees in psychology and forensic studies from Indiana University.